BIOMARIN PHARMACEUTICAL (BMRN) Company Report

The U.S. Food and Drug Administration (FDA) has approved BioMarin Pharmaceutical Inc.'s supplemental Biologics License Application (sBLA) for PALYNZIQ to include pediatric patients 12 years of age and older with phenylketonuria (PKU).
PALYNZIQ is the only enzyme substitution therapy approved to reduce blood phenylalanine (Phe) concentrations in people with PKU.
The approval is based on data from the Phase 3 PEGASUS study, which showed a statistically significant blood phenylalanine (Phe) lowering in the PALYNZIQ arm compared to diet alone at Week 72.
Common adverse reactions in adolescents included injection site reactions, arthralgia, headache, and hypersensitivity reactions; anaphylaxis was reported in 11% of PALYNZIQ-treated patients aged 12 to less than 18 years in a clinical trial.

3 hours ago

Press Release

BioMarin Pharmaceutical Announces Q4 and Full Year 2025 Results

BMRN

Earnings

Revenue Acceleration/Inflection

M&A

BioMarin Pharmaceutical reported a GAAP net loss of $(47) million and Non-GAAP income of $89 million for Q4 2025, with GAAP diluted EPS of $(0.24) and Non-GAAP diluted EPS of $0.46. For the full year 2025, GAAP net income was $349 million and Non-GAAP income was $614 million, with GAAP diluted EPS of $1.80 and Non-GAAP diluted EPS of $3.15.
VOXZOGO revenue reached $273 million in Q4 2025 and $927 million for the full year 2025, marking 26% year-over-year growth.
Enzyme Therapies generated $1,220 million in total revenue for 2025, an 11% increase from 2024, with PALYNZIQ contributing significantly to growth.
Significant upcoming milestones include an anticipated U.S. PDUFA target action date of February 28, 2026, for PALYNZIQ adolescent label expansion, an expected SNDA submission for full approval of VOXZOGO in Q2 2026, and the planned start of the BMN 333 Phase 2/3 study in 1H 2026. Additionally, the acquisition of Amicus, including Pombiliti + Opfolda, is expected to close in Q2 2026.

4 days ago

Presentation

BioMarin Pharmaceutical Reports Strong Q4 and Full Year 2025 Results, Provides 2026 Guidance, and Updates on Acquisitions

BMRN

Earnings

Guidance Update

M&A

BioMarin Pharmaceutical achieved record total revenues of $3.22 billion for the full year 2025, a 13% increase year-over-year, and $875 million for Q4 2025, up 17%. Full-year 2025 non-GAAP diluted earnings per share was $3.15, with underlying business EPS growing approximately 34%.
Voxzogo revenue grew 26% to $927 million for the full year 2025, and enzyme therapies revenue increased 9%. For 2026, the company anticipates total revenues between $3.325 billion and $3.425 billion (excluding Amicus acquisition contributions) and non-GAAP diluted earnings per share in the range of $4.95-$5.15.
The company is expanding its portfolio through the acquisition of Amicus, expected to close next quarter, which will add products like Galafold and Pombiliti/Opfolda to its commercial portfolio. BioMarin also made the strategic decision to withdraw Roctavian from the market, recording approximately $240 million in special items in Q4 2025.
Key pipeline developments include potential Voxzogo indication expansion for hypochondroplasia and the advancement of BMN 333, a next-generation CNP therapy for achondroplasia, with phase 2/3 study enrollment preparing to begin.

4 days ago

Transcript

BioMarin Pharmaceutical Reports Strong 2025 Results and Provides 2026 Guidance

BMRN

Earnings

Guidance Update

M&A

BioMarin Pharmaceutical achieved record total revenues of $3.22 billion for the full year 2025, marking a 13% increase year-over-year, with Q4 2025 revenues at $875 million, up 17%. Full-year 2025 non-GAAP diluted earnings per share was $3.15.
The company issued initial 2026 guidance (excluding Amicus acquisition contributions), forecasting total revenues between $3.325 billion and $3.425 billion and non-GAAP diluted earnings per share in the range of $4.95-$5.15.
Strategic acquisitions include Inozyme, strengthening the enzyme therapies portfolio, and the anticipated Q1 2026 close of Amicus, which will add Galafold, Pombiliti, and Opfolda to the commercial portfolio.
BioMarin decided to withdraw Roctavian from the market, resulting in approximately $240 million in special items in Q4 2025. Additionally, Voxzogo is expected to expand its indication to hypochondroplasia with phase III data readouts in the first half of 2026 and potential approval in 2027.

4 days ago

Transcript

BioMarin Reports Record 2025 Revenues, Provides 2026 Guidance, and Updates on Amicus Acquisition and Pipeline

BMRN

Earnings

Guidance Update

M&A

BioMarin reported record total revenues of $3.22 billion for the full year 2025, a 13% increase year-over-year, driven by a 26% rise in Voxzogo revenues and 9% increase in enzyme therapies revenue. Full-year 2025 non-GAAP diluted earnings per share was $3.15, and operating cash flow increased 45% to $828 million compared to 2024.
The company announced the withdrawal of Roctavian from the market, resulting in approximately $240 million in special items in Q4 2025, including an inventory write-off.
BioMarin anticipates the Amicus acquisition to close next quarter (Q1 2026), which will add Galafold, Pombiliti, and Opfolda to its commercial portfolio, significantly enhancing its 2026 outlook and enabling accelerated revenue growth through the 2030s.
For 2026, excluding Amicus contributions, BioMarin expects total revenues between $3.325 billion and $3.425 billion, with Voxzogo revenue between $975 million and $1.025 billion, and enzyme therapies revenue between $2.225 billion and $2.275 billion. Non-GAAP diluted earnings per share is projected to be in the range of $4.95-$5.15.
Key pipeline milestones for 2026 include anticipated Phase 3 data readouts for Voxzogo in hypochondroplasia and BMN 401 in ENPP1 deficiency, and a PDUFA action date of February 28 for the Palynziq sBLA for adolescents with PKU.

4 days ago

Transcript

BioMarin Reports Q4 and Full-Year 2025 Results, Announces Amicus Acquisition, and Provides 2026 Guidance

BMRN

Earnings

Guidance Update

M&A

BioMarin reported full-year 2025 total revenues of $3.2 billion, a 13% year-over-year increase, and fourth quarter 2025 total revenues of $875 million, up 17% year-over-year.
Revenue growth was primarily driven by VOXZOGO, which increased 26% year-over-year for the full year and 31% in Q4 2025, and Enzyme Therapies, which grew 9% for the full year and 13% in Q4 2025.
The company announced a definitive agreement to acquire Amicus Therapeutics, expected to close in Q2 2026, and voluntarily withdrew ROCTAVIAN from the market, leading to a Q4 2025 GAAP Net Loss of $(47) million.
For full-year 2026, BioMarin provided guidance (excluding any post-close contribution from Amicus) of total revenues between $3,325 million and $3,425 million and Non-GAAP diluted EPS between $4.95 and $5.15.

4 days ago

8-K

BioMarin Reports Q4 and Full-Year 2025 Financial Results, Announces Amicus Acquisition, and Provides 2026 Guidance

BMRN

Earnings

Guidance Update

M&A

BioMarin reported full-year 2025 total revenues of $3.221 billion, a 13% increase year-over-year, and fourth-quarter 2025 total revenues of $875 million, up 17% from the same period in 2024. This growth was notably driven by 26% growth in VOXZOGO revenue and 9% growth in Enzyme Therapies revenue for the full year.
For the fourth quarter of 2025, the company recorded a GAAP Net Loss of $47 million and Non-GAAP Income of $89 million, primarily impacted by approximately $240 million in charges related to the voluntary withdrawal of ROCTAVIAN from the market.
BioMarin announced a definitive agreement to acquire Amicus Therapeutics, with the acquisition expected to close in Q2 2026, aiming to accelerate and diversify revenues.
The company provided full-year 2026 guidance, projecting total revenues between $3.325 billion and $3.425 billion and Non-GAAP Diluted EPS between $4.95 and $5.15, excluding any post-close contribution from the Amicus acquisition.

4 days ago

Press Release

BioMarin Closes Senior Notes Offering to Fund Amicus Therapeutics Acquisition

BMRN

Debt Issuance

M&A

New Projects/Investments

BioMarin Pharmaceutical Inc. closed a private offering of $850 million of 5.500% senior unsecured notes due 2034 on February 12, 2026.
The proceeds from these notes, along with new $2 billion senior secured term loan B facility and $800 million senior secured term loan A facility, and cash on hand, are intended to fund the acquisition of Amicus Therapeutics, Inc..
BioMarin also expects to enter into a $600 million senior secured revolving credit facility in connection with the acquisition.
The gross proceeds from the notes offering are held in an escrow account, and BioMarin will be required to redeem the notes if the acquisition is not completed by December 19, 2026.

Feb 12, 2026, 9:11 PM

8-K

BioMarin Announces Closing of Senior Notes Offering

BMRN

Debt Issuance

M&A

New Projects/Investments

BioMarin Pharmaceutical Inc. closed an offering of $850 million of 5.500% senior unsecured notes due 2034 at an issue price of 100.000%.
The proceeds from the notes, along with borrowings under new $2 billion Term Loan B and $800 million Term Loan A facilities, and cash on hand, will fund the acquisition of Amicus Therapeutics, Inc. and related fees.
BioMarin also expects to enter into a $600 million senior secured revolving credit facility in connection with the acquisition.
The Notes are subject to a special mandatory redemption if the acquisition is not completed by December 19, 2026, requiring redemption at 100% of the initial issue price plus accrued interest.

Feb 12, 2026, 9:05 PM

Press Release

BioMarin Pharmaceutical Inc. Announces Pricing of Senior Notes and Syndication of Term Loan Facilities for Amicus Therapeutics Acquisition

BMRN

Debt Issuance

M&A

New Projects/Investments

BioMarin Pharmaceutical Inc. priced an offering of $850 million of 5.500% senior unsecured notes due 2034, with the offering expected to close on February 12, 2026.
The company completed the syndication of a new $2 billion senior secured term loan "B" facility and an $800 million senior secured term loan "A" facility.
These financing activities, along with cash on hand, are intended to fund the acquisition of Amicus Therapeutics, Inc. and related fees and expenses.
BioMarin also expects to enter into a $600 million senior secured revolving credit facility in connection with the acquisition.
The notes will be subject to mandatory redemption if the acquisition of Amicus Therapeutics, Inc. is not completed on or prior to December 19, 2026.

Jan 29, 2026, 9:19 PM

8-K

Fintool News

In-depth analysis and coverage of BIOMARIN PHARMACEUTICAL.

Deals & Capital Markets

BioMarin Bets $4.8 Billion on Amicus to Create Rare Disease Powerhouse

Dec 19, 2025

View all news

Earnings Transcripts

Quarterly earnings call transcripts for BIOMARIN PHARMACEUTICAL.

Q4 2025

Feb 23, 2026

→

Q3 2025

Oct 27, 2025

→

Q2 2025

Aug 4, 2025

→

View All Transcripts

Ask Fintool AI Agent

Get instant answers from SEC filings, earnings calls & more

What did Alexander Hardy say about margins?What are BIOMARIN PHARMACEUTICAL's strategic priorities?How is BIOMARIN PHARMACEUTICAL positioned vs competitors?How did BIOMARIN PHARMACEUTICAL do last quarter?

BIOMARIN PHARMACEUTICAL (BMRN)

Analyst Earnings Quarterly Reports

Q3 2025

Q2 2025

Q1 2025

Q4 2024

Q4 2025

Executives

Alexander Hardy

Brian R. Mueller

C. Greg Guyer

Cristin Hubbard

G. Eric Davis

Gregory R. Friberg

Board Members

Athena Countouriotis

Barbara W. Bodem

Elizabeth McKee Anderson

Ian T. Clark

Mark J. Enyedy

Maykin Ho

Richard A. Meier

Robert J. Hombach

Timothy P. Walbert

Willard Dere

Analyst Coverage

Cory Kasimov

Philip Nadeau

Akash Tewari

Paul Matteis

Salveen Richter

Jessica Fye

Olivia Brayer

Christopher Raymond

Gena Wang

Joseph Schwartz

Mohit Bansal

Jason Gerberry

Julian Pino

Konstantinos Biliouris

Adam Ferrari

Alexandria Hammond

Allison Bratzel

Andrea Park

Chris Raymond

Eliana Merle

Ellen Horste

Huidong Wang

Jasmine Fels

Joe Schwartz

Kostas Biliouris

Sean Laaman

Sean Lehmann

Tommie Reerink

Addie

Alex Hammond

Ellie Merle

John Wang

Phoebe

Sadia Rehman

Tommy

Vikram Purohit

Zaki Molvi

Latest news

Fintool News

BioMarin Bets $4.8 Billion on Amicus to Create Rare Disease Powerhouse

Earnings Transcripts

Q4 2025

Q3 2025

Q2 2025

Ask Fintool AI Agent